Research Article

An Integrative Bioinformatics Analysis of the Potential Mechanisms Involved in Propofol Affecting Hippocampal Neuronal Cells

Zhao Zhuang,1 Dajiang Li,2 Mengmeng Jiang,2 Ye Wang,2 Qianqian Cao,2 Shenfeng Li,3 Ruixue Luan,1 Lina Sun,1 and Shoushi Wang2

1Academy of Anesthesiology, Weifang Medical University, Weifang, China
2Qingdao Central Hospital, Central Hospital Affiliated to Qingdao University, Qingdao, China
3Academy of Anesthesiology, Qingdao University, Qingdao, China

Correspondence should be addressed to Lina Sun: sun.lina@outlook.com and Shoushi Wang: shoushiwang0502@163.com

Received 14 February 2022; Revised 22 March 2022; Accepted 29 March 2022; Published 26 April 2022

1. Introduction

Propofol is one of the intravenous hypnotic medicines used to induce and maintain sedation and general anesthesia. It exerts its action through potentiation of the inhibitory neurotransmitter γ-aminobutyric acid at the GABA-A receptor [1, 2]. It is highly lipophilic and thus can rapidly cross the blood-brain barrier, leading to early onset of action. The characteristics of propofol are well known. It has fast metabolism and short recovery time, regardless of the depth or length of sedation time [3]. In addition to being used as an anesthetic, researchers also found that propofol is also related to many cancer-related pathophysiological processes and can play an important role in cancer by regulating the expression of a variety of downstream molecules, long-chain noncoding RNA, microRNA, and signal pathways [4]. Propofol upregulates miR-195, and then JAK/stat and NF-κB pathway is inactivated to inhibit the proliferation, migration, and invasion of gastric carcinoma MKN45 cells [5].

Although propofol can play an excellent role in maintaining sedation and general anesthesia, studies have also focused on changes in regional cerebral blood flow or neuronal activity during propofol sedation. Only one study showed that as the depth of propofol sedation increased, the activity in the area corresponding to the stimulus applied during propofol sedation decreased. In addition, they found that propofol sedation impaired the function of basal ganglia circuits and thalamocortical connections [6].
understood that learning and memory occur mainly in the hippocampus, and propofol may cause hippocampal neurotoxicity [7, 8]. General anesthetics may induce developmental neurotoxicity, including subsequent long-term memory, acute extensive nerve cell death, and abnormal learning behavior [9]. Although many researchers have figured out that propofol induced neurotoxicity in the brains of developing animals, its exact mechanism of action remains largely unknown. Then, this manuscript, on the other hand, was conducted to observe the potential biological processes and signaling pathways that may play an important role during propofol sedation through the biology information analysis of genes with different expression patterns.

2. Methods

2.1. Cell Processing and Sequencing. The HT22 hippocampal cell line used in the present study was purchased from Shanghai Yaji Biotechnology Co. (Shanghai, China). The cells were fostered in DMEM containing 10% FBC, 100 μg/mL penicillin, 100 ng/mL streptomycin at 37°C, and 5% CO₂. When the cell density reached 60–70%, the HT22 cells were exposed to propofol at concentrations of 25 μg/ml, 50 μg/ml, 75 μg/ml, and 100 μg/ml for 1 day. The experiment was repeated three times. The cDNA/DNA/Small RNA was sequenced on the Illumina sequencing platform by Genednovo Biotechnology (Guangzhou, China). The libraries were sequenced.

2.2. Effects of Treatment on CCK-8. Cells were inoculated in 96-well plates at 1 x 10³ cells per well. Cell Counting Kit-8 (CCK-8; Beyotime Biotechnology, Shanghai, China) assays were performed daily. Briefly, the cells were incubated in a 100 μL medium containing 10 μL of CCK-8 (0.5 mg/mL) reagent at 37°C for one to four hours. Absorbance was measured at 450 nm by an enzyme-labeled assay (Figure 1). The experiment was performed at least three times in three replicate wells.

2.3. Trend Analysis. The results obtained from sequencing were subjected to follow-up experiments. The expression of each gene was grouped according to different concentration points, and then a dynamic trend analysis was completed using OmicShare Tools. A P value <0.05 would show a significant difference.

2.4. Protein-Protein Interaction (PPI) Network Construction. All associations got from STRING were provided with a confidence score and imported into Cytoscape software. Modules of the PPI network were screened using the Molecular Complex Detection plugin in Cytoscape. A P value <0.05 would show a significant difference.

2.5. Gene Ontology (GO) Function. Gene ontology annotations and KEGG pathway enrichment analyses were performed using the Enrichr database GO terms consisting of the following three components: biological process (BP), cellular component (CC), and molecular function (MF).

2.6. WGCNA Analysis. Co-expression networks were constructed using the WGCNA data bank in R software. Paired Pearson correlations were first used to evaluate the weighted co-expression relationships between all subjects in the dataset in the adjacency matrix. The matrices were then converted to TOMs using the topological overlap matrix (TOM) similarity function, and the resulting TOMs were used to measure co-expression relationships between genes based on biologically meaningful genetic similarity.

2.7. GSEA Analysis. The genes were classified into high and low-expression parts, and then GSEA V3.0 software was used to analyze the enrichment results for the genes. A nominal P value of <0.05 and false discovery rate (FDR) of <25% were selected as cut-off criteria. We selected the top two ranked analysis results.

3. Results

3.1. Trend Analysis. We first subjected the expression data obtained from sequencing to trend analysis to observe the genes whose expression continued to increase or decrease with increasing propofol concentration. The results of the trend analysis showed that genes concentrated in module 0 decreased in expression with increasing propofol concentration, and genes concentrated in module 19 increased in expression with increasing propofol concentration; both panels were differentially significant. There were 2,506 genes in module 0 and 1,871 genes in module 19 (see Figure 2).

3.2. Heat Map Showing the Expression of Each Gene in Each Sample. Subsequently, we selected statistically significant modules for expression pattern clustering analysis. The heat map shows the expression of each trend module gene in each group of samples (see Figure 3).

3.3. WGCNA Analysis. We selected module 0, in which gene expression was downregulated with propofol concentration, and module 19, in which gene expression increased with...
Profile 0 : 2506 Genes
Profile 1 : 91 Genes
Profile 10 : 17 Genes
Profile 11 : 233 Genes
Profile 16 : 69 Genes
Profile 15 : 33 Genes
Profile 14 : 11 Genes
Profile 13 : 62 Genes
Profile 12 : 336 Genes
Profile 17 : 215 Genes
Profile 4 : 13 Genes
Profile 3 : 3 Genes
Profile 2 : 7 Genes
Profile 19 : 1871 Genes
Profile 18 : 983 Genes
Profile 5 : 3 Genes
Profile 6 : 149 Genes
Profile 7 : 104 Genes
Profile 8 : 448 Genes
Profile 9 : 6 Genes

Profile ordered based on the p-value significance of number of Genes assigned versus expected

(a)

(b)

Figure 2: Continued.
propofol concentration; we collected genes from both modules for WGCNA analysis. The analysis identified a total of two panels, in which the turquoise panel genes were negatively correlated with the treatment of propofol (see Figure 4).

3.4. PPI Network Construction. We selected the genes with Cor R > 0.9 in the turquoise panel, a total of 1,698 genes, to construct the PPI network. Subsequently, the top 5 key genes, i.e., CD86, IL10RA, PTPRC, SPI1, and ITGAM, were screened using the MCC algorithm (see Figure 5).

3.5. GSEA Analysis. We grouped the samples as high and low parts, while GSEA analysis was performed on single genes afterward. The analysis figured out that the low expression of CD86, IL10RA, PTPRC, SPI1, and ITGAM all have important roles in the PRION_DISEASES pathway, and CD86, PTPRC, SPI1, and ITGAM are also all involved in the NUCLEOTIDE_EXCISION_REPAIR signaling pathway. Furthermore, IL10RA is involved in the CIRCADIAN_RHYTHM_MAMMAL signaling pathway (see Figure 6).

4. Discussion

Propofol causes fewer anesthetic side effects and facilitates faster recovery compared to other intravenous anesthetics. The benefits of propofol include the rapid onset of anesthesia, short recovery time, and neuroprotective effects in pathogenic situations [8, 10]. Hence, concerns have been raised about the possible effects of the widespread use of propofol on the central nervous system. Propofol does have neurotoxic effects on children. It affects brain development by inhibiting neuronal activation of hippocampal neurons, which may lead to the reduction of neurocognitive function [11]. Animal experiments have shown that exposure to high doses of isoproterenol inhibits long-term potentiation in the CA1 region of the adult hippocampus [12]. Previous studies have suggested that this may be because propofol is the most potent drug for activating the GABA-A currents in the immature hypothalamus [13]. To date, the specific molecular mechanisms involved in propofol affecting the hippocampal neuronal cells still remain unclear. To find the potential mechanisms by which propofol may affect hippocampal neuronal cells, we performed a trend analysis of the results obtained from sequencing. We found that 2,506 genes may decrease in expression with increasing propofol concentrations, and 1,871 genes may increase in expression with increasing propofol concentrations. We then selected these 4,377 genes to WGCNA analysis and found that the turquoise plate genes were significantly and negatively correlated with the propofol in your treatment group. We then selected the genes in this panel with correlation coefficients greater than 0.9 for PPI network construction and screened five key genes: CD86, IL10RA, PTPRC, SPI1, and ITGAM.

CD86 is a type I transmembrane protein associated with T-cell activation in the immune system [14]. CD86 may act as a key regulator of the immune response to disease through a T-cell-mediated mechanism, and thus it has great potential to become a new target for immunotherapy [15]. IL10RA consists mainly of a heterotetramer of the anti-inflammatory cytokine IL10 receptor and belongs to class II cytokines [16, 17]. IL10RA is usually located as a cell surface receptor upstream of STAT3, and it can bind IL-10 together with IL10RB to mediate downstream signaling via STAT3 [18]. PTPRC is expressed on all nucleated cells of the hematopoietic system. It expresses several isoforms specific to a certain cell type and cell development or activation state [19]. PTPRC also plays an important role in autoimmune diseases and cancers, as well as in infectious diseases; its deficiency may lead to T and B lymphocyte dysfunction, manifesting as severe combined immunodeficiency [20].

SPI1 is a major regulator of hematopoiesis because it is involved in the self-renewal of hematopoietic stem and progenitor cells, as well as in the stereotyping and
maturation of the myeloid and B-lymphatic lineages. Inappropriate Spi1 expression is oncogenic. However, the molecular mechanisms mediating the oncogenic function of Spi1 are complex and not yet fully understood [21]. In addition, Spi1 transcription factors are important in regulating macrophage and neutrophil development [22]. ITGAM is expressed by a variety of myeloid cell types, which can form heterodimers with CD18 and mediate adhesion between cell types in the immune system [23, 24]. ITGAM deficiency may enhance disease progression and inflammation in multiple autoimmune models, including lupus [25]. The above then could show that CD86, IL10RA, PTPRC, SPI1, and ITGAM all play important roles in immune response. Inflammation is a response triggered by damage to living tissue. It can be beneficial or may lead to tissue destruction. Inflammation is particularly dangerous when the nervous system is involved (so-called “neuroinflammation”), whether acute or chronic [26]. In turn, neuroinflammation can cause reversible and irreversible neurological sequelae, including cognitive impairment [27]. However, by modulating inflammation, it is also possible to improve peripheral nerve repair [28]. It has been suggested that the abnormal expression of CD86, IL10RA, PTPRC, SPI1, and ITGAM may trigger an immune-inflammatory response and thus lead to neurological damage.

In the present experiment, we performed GSEA analyses of individual genes separately and showed that CD86, IL10RA, PTPRC, SPI1, and ITGAM are involved in the PRION_DISEASES pathway. Prion diseases can make the prion protein (PrP Sc) in the central nervous system itch. In the early stages, microglia respond to the deposition of PrP Sc, thereby increasing their phagocytic capacity to clear PrP Sc. However, this phagocytosis is not sufficient and can have detrimental effects on the brain [29]. This is further evidence...

Figure 3: Heatmap showing the expression of each gene in each sample. (a) Heatmap of module 0 gene expression in each sample. (b) Heatmap of module 19 gene expression in each sample. (c) Heatmap of module 18 gene expression in each sample. (d) Heatmap of module 12 gene expression in each sample.
Figure 4: WGCNA analysis. (a) Heat map of correlations between (a) soft threshold (b) module signature genes and propofol treatment groups.
Figure 5: PPI network construction. (a) PPI network building block diagram. (b) 5 key genes obtained from MCC algorithm analysis.
Figure 6: Continued.
that CD86, IL10RA, PTPRC, SPI1, and ITGAM have an important relationship in neurological impairment of the brain. This could also suggest that propofol may lead to neurological impairment by affecting the abnormal expression of CD86, IL10RA, PTPRC, SPI1, and ITGAM; thus, the exact mechanism remains to be investigated.

5. Conclusion

In conclusion, CD86, IL10RA, PTPRC, SPI1, and ITGAM may play an important role in propofol affecting mouse hippocampal neuronal cells. Propofol may affect mouse hippocampal neurons by affecting the expression of PTPRC, CD86, IL10RA, SPI1, and ITGAM. Thereby, these findings may imply potential new targets for the treatment of patients with propofol anesthesia-induced neurological injury.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.
References

[1] M. M. Sahinovic, M. M. R. F. Struys, and A. R. Absalom, “Clinical pharmacokinetics and pharmacodynamics of propofol,” *Clinical Pharmacokinetics*, vol. 57, no. 12, pp. 1539–1558, 2018.

[2] L. Chen, Z.-l. Yang, J. Cheng et al., “Propofol decreases the excitability of cholinergic neurons in mouse basal forebrain via GABAA receptors,” *Acta Pharmacologica Sinica*, vol. 40, no. 6, pp. 755–761, 2019.

[3] T. Nishizawa and H. Suzuki, “Propofol for gastrointestinal endoscopy,” *United European Gastroenterology Journal*, vol. 6, no. 6, pp. 801–805, 2018.

[4] Y. Xu, S. Pan, W. Jiang, F. Xue, and X. Zhu, “Effects of propofol on the development of cancer in humans,” *Cell Proliferation*, vol. 53, no. 8, Article ID e12867, 2020.

[5] W. Zhang, Y. Wang, Z. Zhu, Y. Zheng, and B. Song, “Retracted: propofol inhibits proliferation, migration and invasion of gastric cancer cells by up-regulating microRNA-195,” *International Journal of Biological Macromolecules*, vol. 120, no. A, pp. 975–984, 2018.

[6] R. N. Mhuircheartaigh, D. Rosenorn-Lanng, R. Wise, S. Jbabi, R. Rogers, and I. Tracey, “Cortical and subcortical connectivity changes during decreasing levels of consciousness in humans: a functional magnetic resonance imaging study using propofol,” *Journal of Neuroscience*, vol. 30, no. 27, pp. 9095–9102, 2010.

[7] S. Zhang, Z. Liang, W. Sun, and L. Pei, “Repeated propofol anesthesia induced downregulation of hippocampal miR-132 and learning and memory impairment of rats,” *Brain Research*, vol. 1670, pp. 156–164, 2017.

[8] X. Li, L. Yao, Q. Liang, H. Qu, and H. Cai, “Propofol protects hippocampal neurons from hypoxia-reoxygenation injury by decreasing calcineurin-induced calcium overload and activating YAP signaling.” *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 1725191, 12 pages, 2018.

[9] L. Feng, Z. G. Sun, Q. W. Liu et al., “Propofol inhibits the expression of Abelson nonreceptor tyrosine kinase without affecting learning or memory function in neonatal rats,” *Brain and behavior*, vol. 10, no. 11, Article ID e01810, 2020.

[10] N. Berndt, U. Haq, O. Kovacs et al., “Possible neurotoxicity of the anesthetic propofol: Evidence for the inhibition of complex II of the respiratory chain in area CA3 of rat hippocampal slices,” *Archives of Toxicology*, vol. 92, no. 10, pp. 3191–3205, 2018.

[11] Y. Yang, J. Yi, M. Pan, B. Hu, and H. Duan, “Edaravone alleviated propofol-induced neurotoxicity in developing Hippocampus by mBDNF/TrkB/P13K pathway,” *Drug Design, Development and Therapy*, vol. 15, pp. 1409–1422, 2021.

[12] R. Guan, J. Ly, F. Xiao, Y. Tu, Y. Xie, and L. Li, “Potential role of the cAMP/PKA/CREB signalling pathway in hypoxic preconditioning and effect on propofol-induced neurotoxicity in the hippocampus of neonatal rats,” *Molecular Medicine Reports*, vol. 20, no. 2, pp. 1837–1845, 2019.

[13] V. Tesic, S. M. Joksimovic, N. Quillinan et al., “Neuroactive steroids alphaxalone and CDNC24 are effective hypnotics and potentiators of GABA receptors, but are not neurotoxic to the developing rat brain,” *British Journal of Anaesthesia*, vol. 124, no. 5, pp. 603–613, 2020.

[14] J. Fang, H. Ying, T. Mao et al., “Uregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells,” *Oncotarget*, vol. 8, no. 49, pp. 85085–85101, 2017.

[15] H. Qiu, W. Tian, Y. He et al., “Integrated analysis reveals prognostic value and immune correlates of CD86 expression in lower grade glioma,” *Frontiers in Oncology*, vol. 11, Article ID 654350, 2021.

[16] F. A. Al-Abbesi, K. Mohammed, S. Sadath, B. Bananapanalli, K. Nasser, and N. A. Shaik, “Computational protein phenotype characterization of IL10RA mutations causative to early onset inflammatory bowel disease (IBD),” *Frontiers in Genetics*, vol. 9, p. 146, 2018.

[17] A.-J. Xue, S.-I. Miao, H. Sun et al., “Intestinal dysbiosis in pediatric Crohn’s disease patients with IL10RA mutations,” *World Journal of Gastroenterology*, vol. 26, no. 22, pp. 3098–3109, 2020.

[18] N. Prokoph, N. A. Probst, L. C. Lee et al., “IL10RA modulates criptinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma,” *Blood*, vol. 136, no. 14, pp. 1657–1669, 2020.

[19] J. Landskron, S. M. Krägerud, E. Wik et al., “C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease,” *Plos One*, vol. 12, no. 7, Article ID e0182030, 2017.

[20] A. Rheinländer, B. Schraven, and U. Bommhardt, “CD45 in human physiology and clinical medicine,” *Immunology Letters*, vol. 196, pp. 22–32, 2018.

[21] P. Rimmelé, M. Esposito, L. Delestré et al., “The Spi1/Pu.1 transcription factor accelerates replication fork progression by increasing PP1 phosphatase in leukemia,” *Oncotarget*, vol. 8, no. 23, pp. 37104–37114, 2017.

[22] A. Zakrzewska, C. Cui, O. W. Stockhammer, E. L. Benard, H. P. Spaink, and A. H. Meijer, “Macrophage-specific gene functions in Spi1-directed innate immunity,” *Blood*, vol. 116, no. 3, pp. el–e11, 2010.

[23] G. Horn, R. R. Graham, B. Modrek et al., “Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX,” *New England Journal of Medicine*, vol. 358, no. 9, pp. 900–909, 2008.

[24] J. L. Dunne, R. G. Collins, A. L. Beaudet, C. M. Ballantyne, and K. Ley, “Mac-1, but not LFA-1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNF-α-induced inflammation,” *The Journal of Immunology*, vol. 171, no. 11, pp. 6105–6111, 2003.

[25] J. Ramirez-Bello, C. Sun, G. Valencia-Pacheco et al., “ITGAM is a risk factor to systemic lupus erythematosus and possibly a protection factor to rheumatoid arthritis in patients from Mexico,” *Plos One*, vol. 14, no. 11, Article ID e224543, 2019.

[26] S. D. Skaper, L. Facci, M. Zusso, and P. Giusti, “An inflammation-centric view of neurological disease: beyond the neuron,” *Frontiers in Cellular Neuroscience*, vol. 12, p. 72, 2018.

[27] A. Alam, Z. Hana, Z. Jin, K. C. Suen, and D. Ma, “Surgery, neuroinflammation and cognitive impairment,” *EBioMedicine*, vol. 37, pp. 547–556, 2018.

[28] T.-C. Huang, H.-L. Wu, S.-H. Chen, Y.-T. Wang, and C.-C. Wu, “Thrombomodulin facilitates peripheral nerve regeneration through regulating M1/M2 switching,” *Journal of Neuroinflammation*, vol. 17, no. 1, p. 240, 2020.

[29] A. Aguzzi and C. Zhu, “Microglia in prion diseases,” *Frontiers in Immunology*, vol. 8, no. 27, Article ID e0182030, 2017.